Xcout Intel
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company dedicated to delivering transformational medicines, such as QINLOCK, to patients for the treatment of cancer and rare diseases.
Subscribe to see Deciphera Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Deciphera Pharmaceuticals at a glance
Deciphera Pharmaceuticals is a pharmaceuticals company headquartered in United States, founded in 2003. It has raised at least $169.9M across the 4 funding rounds on record. Its most recent funding round, Series C, raised $52.3M in May 2017. Xcout tracks 1 named person at Deciphera Pharmaceuticals, including Daniel L. Flynn, PhD (Founder). Xcout recorded 37 job postings from Deciphera Pharmaceuticals in the last 90 days, naming tools such as Oracle ERP, SAP, Salesforce.
Deciphera Pharmaceuticals leadership
- Daniel L. Flynn, PhDFounder
Deciphera Pharmaceuticals funding rounds
At least $169.9M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $52.3M | — | |
| Series B | $15M | — | |
| SEC Form D filing | $90.6M | — | |
| Series A | $12M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Deciphera Pharmaceuticals
Xcout recorded 37 job postings from Deciphera Pharmaceuticals in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Deciphera Pharmaceuticals's job postings
The weekly hiring trend, the roles and locations behind it — see Deciphera Pharmaceuticals's hiring signals →
Hiring vs the trend
Based on 30 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 168 enterprise healthcare companies.
This describes a hiring pattern — how often Deciphera Pharmaceuticals’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Tech stack
Deciphera Pharmaceuticals competitors
A few of Deciphera Pharmaceuticals's closest competitors — see the full list of competitors and alternatives →
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare and orphan diseases.
Shorla Pharma (operating as Shorla Oncology) develops and commercializes innovative oncology drugs, focusing on indications where existing treatments are limited, in shortage, or inadequate. The company provides specialized cancer treatments and accessible pharmaceutical options for patients.
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Radius Health is a commercial biopharmaceutical company that offers a growing portfolio of differentiated specialty medicines, including products like TYMLOS.
Boston Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company that acquires, develops, and advances drug candidates for serious diseases. It works with pharmaceutical and biotechnology partners to bring clinical-stage medicines toward commercialization and serves patients with significant unmet medical needs.
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.
Get Deciphera Pharmaceuticals's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Deciphera Pharmaceuticals in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access